

LEO Pharma Timeline

Dermatology
beyond the skin



The early days 1908–1929

1910
3 employees

1914
Operations in Sweden initiated

1926
80 employees

1939–40
200+ employees

Entering biotech 1930–1984

1908

1909

1912

1917

1923–25

1930

1936

1939–40

1945

1946–48

1949–51

Pharmacists Anton Antons and August Kongsted receive royal privilege from King Frederik VIII to operate LEO Pharmacy, (Løveapoteket, originally founded in 1620), in Copenhagen, Denmark, and establish LEO Pharma.



August Kongsted



Anton Antons

LEO Pharmacy establishes a bacteriological and pharmacophysiological laboratory.

Here, the production of sterile and standardized preparations is initiated, and an inhalatorium for respiratory patients is established.



LEO Pharma's first location in Copenhagen, Denmark

Albyl® is launched and remains the most popular painkiller in Denmark for decades.



The original LEO Pharma logo is inspired by the Assyrian lions found in Nebuchadnezzar's palace in Babylon

In the newly established laboratories Dr. Marie Krogh standardises digitalis, making Digisolvin LEO® is the first Danish drug to be exported.



Waiting room in the inhalatorium situated above the LEO Pharmacy

LEO Pharma initiates insulin production and finances the development and production of insulin in the 1920s.

In 1925, the insulin production is transferred to the independent Nordisk Insulinlaboratorium.



LEO Pharma develops a number of hormone products.

Some hormones are extracted from the urine of pregnant women.



LEO Pharma staff collects urine on pushbikes

Heparin extraction method is developed.



Bottles being filled at LEO Pharma

Heparin® is launched.

August Kongsted passes away. His son-in-law Knud Abildgaard, is appointed CEO of LEO Pharma.

LEO Pharma's price list now contains approx. 230 branded products.



August Kongsted 1870–1939

LEOPenicillin® is launched.

LEO Pharma is the first company outside of the UK and the US to manufacture penicillin.

The new life-saving drug, is considered a medical miracle.



Penicillin production plants are established under licence in Italy, Spain and France.

The first bricks for LEO Pharma's new headquarters are laid in Ballerup, Denmark.

LEO Pharma starts export of pharmaceutical products.

Protaminsulphat LEO® is launched in 1951.

From 1949 to 1959, LEO Pharma moves production to the new headquarters in Ballerup, Denmark.



LEO Pharma's head quarters in Ballerup, Denmark



1958
Operations in France, Holland, Ireland & Greece initiated

1960
Operations in the UK initiated & new operations initiated in Sweden

1958
2500 employees

1962
Operations in Norway initiated

1979
Operations in the Middle East initiated

1977
Operations in Belgium initiated

1983
Operations in Canada initiated

1988
Operations in Poland & Asia initiated

Global expansion 1985-2008

1956

1958

1962

1971

1973

1976

1978

1984

1985

1986

1987

LEO Pharma's logo is registered as the official trademark.



Rontyl® is launched.



In 1958, at the 50th anniversary of the company, Abildgaard is given a lion cub. The lion is donated to the Copenhagen Zoo.

Fucidin® is launched.

Fucidin® is based on fusidic acid, a new antibiotic substance derived from the fungus *Fusidium coccineum*, discovered by LEO Pharma scientists in 1959.




Pondocillin® is launched.

The next new generation of penicillins is launched.



LEO Pharma research into vitamin D analogues begins.




LEO Pharma's Heparin production plant in Esbjerg, Denmark is established.

One-Alpha® is launched.

The LEO Foundation is established.



The D vitamin analogue, calcipotriol, is synthesized.



Fucidin® H is launched.

Knud Abildgaard passes away.

LEO Pharma is now fully owned by the LEO Foundation.



Knud Abildgaard 1901-1986

Fucicort® is launched.



1990
Operations
in Finland
initiated

1992
Operations
in Germany
initiated

1995
Operations
in Spain
initiated

1997
Operations
in Portugal
initiated

1991
Operations
in Switzerland
initiated

1994
4,250
employees
worldwide

1996
Operations
in Austria
initiated

2001
Operations
in Morocco
initiated

2002
Operations
in Algeria
initiated

2003
Operations
in Tunisia
initiated

2009
Operations
in the US, China
& Australia
initiated

2010
Operations
in Brazil, Japan
& Mexico
initiated

2011
Operations
in Italy, Turkey
& South Korea
initiated

Focus on dermatology

1991

1994

1998

2000

2001

2002

2003

2005

2008

2009

2011


Daivonex®/
Dovonex® and
Innohep® are
launched.



Daivonex® is
awarded the
prestigious
Belgian
pharmaceutical
award Prix
Galien.



An R&D
facility
state-of-
the-art
facilities is
built in
Ballerup.




LEO Pharma
R&D
facilities in
Ballerup,
Denmark

LEO Pharma is
awarded an
environmental
award,
København
Amt Miljøpris
as well as King
Frederik IX's
Award for
Excellence in
Export.



LEO Pharma
manages to
combine two
unmixable
compounds:
calcipotriol and
betametha-
sone dipro-
pionate, and
Daivobet®/
Dovobet® is
launched.



LEO Pharma
changes the
Danish
company
name from
Løvens
Kemiske Fabrik
to LEO
Pharma.



Daivobet®/
Dovobet®
receives the
Confederation
of Danish
Industries'
Product Award.

Daivobet®/
Dovobet® is
approved in
the US under
the name
Taclonex®.

Xamiol®
is launched.

Taclonex
Scalp® Topical
Suspension
approved in
the US.

LEO Pharma
celebrates its
100years
anniversary.



LEO Pharma
introduces its
new mission:
'We help
people
achieve
healthy skin'.



2012-13

Picato® is launched.

2014

LEO Pharma Open Innovation is established: a collaborative space created to explore partnerships and the latest research using some of LEO Pharma's unique scientific resources.

openinnovation.leo-pharma.com

2015

LEO Pharma acquires dermatology portfolio from Astellas.

LEO Pharma establishes LEO Innovation Lab: pursuing digital solutions to help people with skin diseases.



2016

Enstilar® is launched.

LEO Pharma enters biologics through strategic partnership with AstraZeneca.

LEO Pharma establishes LEO Science & Tech Hub in Boston: exploring cutting-edge science and technology opportunities with relevance to dermatology.

LEOSCIENCE & TECHHUB

2017

2017
LEO Pharma builds R&D hub in China.

Kyntheum®, LEO Pharma's first biologic treatment for psoriasis, is launched

LEO Pharma passes revenue of more than DKK 10 billion for the first time.

2018

2018
5200 employees

LEO Pharma acquires Bayer's prescription dermatology business.

2019

2019
5500 employees

LEO Pharma breaks ground for the new Fucidin® Active Pharmaceutical Ingredient production plant in Ballerup, Denmark.



Visualization of LEO Pharma's new API production plant in Ballerup, Denmark

2020

LEO Pharma's pipeline is extended with IL-17 small-molecule modulator.

LEO Pharma enters license agreement with Oneness Biotech and Microbio Shanghai for FB825, a novel atopic dermatitis and asthma drug candidate.

